Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments

Grant Theron, Jonny Peter, Greg Calligaro, Richard Meldau, Colleen Hanrahan, Hoosain Khalfey, Brian Matinyenya, Tapuwa Muchinga, Liezel Smith, Shaheen Pandie, Laura Lenders, Vinod Patel, Bongani M Mayosi, Keertan Dheda, Grant Theron, Jonny Peter, Greg Calligaro, Richard Meldau, Colleen Hanrahan, Hoosain Khalfey, Brian Matinyenya, Tapuwa Muchinga, Liezel Smith, Shaheen Pandie, Laura Lenders, Vinod Patel, Bongani M Mayosi, Keertan Dheda

Abstract

The determinants of Xpert MTB/RIF sensitivity, a widely used PCR test for the diagnosis of tuberculosis (TB) are poorly understood. We compared culture time-to-positivity (TTP; a surrogate of bacterial load), MTB/RIF TB-specific and internal positive control (IPC)-specific C(T) values, and clinical characteristics in patients with suspected TB who provided expectorated (n = 438) or induced sputum (n = 128), tracheal aspirates (n = 71), bronchoalveolar lavage fluid (n = 152), pleural fluid (n = 76), cerebral spinal fluid (CSF; n = 152), pericardial fluid (n = 131), or urine (n = 173) specimens. Median bacterial load (TTP in days) was the strongest associate of MTB/RIF positivity in each fluid. TTP correlated with C(T) values in pulmonary specimens but not extrapulmonary specimens (Spearman's coefficient 0.5043 versus 0.1437; p = 0.030). Inhibition affected a greater proportion of pulmonary specimens than extrapulmonary specimens (IPC C(T) > 34: 6% (47/731) versus 1% (4/381; p < 0.0001). Pulmonary specimens had greater load than extrapulmonary specimens [TTPs (interquartile range) of 11 (7-16) versus 22 (18-33.5) days; p < 0.0001]. HIV-infection was associated with a decreased likelihood of MTB/RIF-positivity in pulmonary specimens but an increased likelihood in extrapulmonary specimens. Mycobacterial load, which displays significant variation across different body compartments, is the main determinant of MTB/RIF-positivity rather than PCR inhibition. MTB/RIF C(T) is a poor surrogate of load in extrapulmonary specimens.

Conflict of interest statement

Keertan Dheda is an editor for Sci Reports.

Figures

Figure 1. Comparison of culture days-to-positivity (A…
Figure 1. Comparison of culture days-to-positivity (A and B) and Xpert MTB/RIF CT values (C and D) in different fluids, and in pulmonary specimens versus extrapulmonary specimens.
Asterisks indicate specimen types with significantly lower bacterial load than expectorated sputum or pulmonary specimens. Abbreviations: BALF, bronchoalveolar lavage fluid; CSF, cerebral spinal fluid. No urine specimens were culture-positive.
Figure 2. Scatter plots of days-to-positivity in…
Figure 2. Scatter plots of days-to-positivity in different types of liquid culture-positive specimens obtained from separate patient cohorts.
Each circle represents an individual specimen. Solid circles indicate specimens which were Xpert MTB/RIF-positive, whereas empty circles indicate Xpert MTB/RIF-negative specimens. Comparisons below each graph are between median (IQR) TTPs for Xpert-MTB/RIF-positive vs. –negative specimens for that fluid. *Only one MTB/RIF-negative, culture-positive tracheal aspirate specimen was present; Fluids from the lung include expectorated sputum, induced sputum, tracheal aspirates, and bronchoalveolar lavage fluid; Fluids from elsewhere in the body include pleural fluid, cerebral spinal fluid, and pericardial fluid. No patients had culture-positive urine.
Figure 3. Scatter plots of Xpert MTB/RIF…
Figure 3. Scatter plots of Xpert MTB/RIF internal positive control (IPC) cycle threshold values in different types of culture-positive specimens obtained from separate patient cohorts.
Each circle represents an individual specimen. Solid circles indicate patients who were Xpert MTB/RIF-positive, whereas empty circles indicate Xpert MTB/RIF-negative specimens. Comparisons are between median (IQR) IPC CTs for Xpert-MTB/RIF-positive vs. –negative specimens. *Only one MTB/RIF-negative, culture-positive tracheal aspirate specimen and one MTB/RIF-negative, culture-positive BALF specimen were present; Pulmonary specimens include expectorated sputum, induced sputum and bronchoalveolar lavage fluid; Extrapulmonary specimens include tracheal aspirates, pleural fluid, cerebral spinal fluid, and pericardial fluid. No patients had culture-positive urine.
Figure 4. Correlation between liquid culture time-to-positivity…
Figure 4. Correlation between liquid culture time-to-positivity and Xpert MTB/RIF cycle threshold values in (A) pulmonary specimens and (B) extrapulmonary specimens.

References

    1. Raviglione M. et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379, 1902–1913 (2012).
    1. Dowdy D. W., Chaisson R. E., Maartens G., Corbett E. L. & Dorman S. E. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. PNAS 105, 11293 (2008).
    1. Hepple P., Ford N. & McNerney R. Microscopy compared to culture for the diagnosis of tuberculosis in induced sputum samples: a systematic review. IJTLD 16, 579 (2012).
    1. Light R. W. Update on tuberculous pleural effusion. Respirology 15, 451–458 (2010).
    1. Vadwai V. et al. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J. Clin. Microbiol. 49, 2540–2545 (2011).
    1. Dheda K., Lampe F. C., Johnson M. A. & Lipman M. C. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J. Infect. Dis. 190, 1670 (2004).
    1. Steingart K. et al. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev; 10.1002/14651858.CD009593.pub3 (2013).
    1. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resitance: Xpert MTB/RIF PUBLIC "-//NPG//DTD XML Article//EN". Publication number WHO/HTM/TB/2011.4. (2011). Available from (last accessed 7 June 2014).
    1. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Publication number WHO/HTM/TB/2013.14. (2013) Available from (last accessed 7 June 2014).
    1. Federal Drug Administration. Press release: FDA permits marketing of first U.S. test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin. Available from (last accessed 13 January 2014).
    1. Blakemore R. et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 48, 2495–2501 (2010).
    1. Helb D. et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48, 229–237 (2010).
    1. Lawn S. D. et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8, e1001067 (2011).
    1. Causse M., Ruiz P., Gutiérrez-Aroca J. B. & Casal M. Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. J. Clin. Microbiol. 49, 3065–3067 (2011).
    1. Friedrich S. O., von Groote-Bidlingmaier F. & Diacon A. H. Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. J. Clin. Microbiol. 49, 4341–4342 (2011).
    1. Hillemann D., Rüsch-Gerdes S., Boehme C. & Richter E. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J. Clin. Microbiol. 49, 1202–1205 (2011).
    1. Miller M. B., Popowitch E. B., Backlund M. G. & Ager E. P. C. Performance of Xpert MTB/RIF RUO Assay and IS6110 Real-Time PCR for Mycobacterium tuberculosis Detection in Clinical Samples. J. Clin. Microbiol. 49, 3458 (2011).
    1. Moure R. et al. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J. Clin. Microbiol. 49, 1137–1139 (2011).
    1. Tortoli E. et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur. Respir. J. 40, 442–447 (2012).
    1. Peter J. G., Theron G., Muchinga T. E., Govender U. & Dheda K. The Diagnostic Accuracy of Urine-Based Xpert MTB/RIF in HIV-Infected Hospitalized Patients Who Are Smear-Negative or Sputum Scarce. PloS one 7, e39966 (2012).
    1. Zeka A. N., Tasbakan S. & Cavusoglu C. Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. J. Clin. Microbiol. 49, 4138–4141 (2011).
    1. Christopher D. J. et al. Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis. Eur. Respir. J. 42, 1427–1429 (2013).
    1. Theron G. et al. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 68, 1043–51 (2013).
    1. Shenai S. et al. Exploring Alternative Biomaterials for Diagnosis of Pulmonary Tuberculosis in HIV-Negative Patients by Use of the GeneXpert MTB/RIF Assay. J. Clin. Microbiol. 51, 4161–4166 (2013).
    1. Banada P. P., Koshy R. & Alland D. Detection of Mycobacterium tuberculosis in Blood by Use of the Xpert MTB/RIF Assay. J. Clin. Microbiol. 51, 2317–2322 (2013).
    1. Malbruny B., Le Marrec G., Courageux K., Leclercq R. & Cattoir V. Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples [Technical note]. IJTLD 15, 553–555 (2011).
    1. Fennelly K. P. An eXpert AFB Smear? Clin. Infect. Dis. 54, 389–391 (2012).
    1. Theron G. et al. The Use of an Automated Quantitative Polymerase Chain Reaction (Xpert MTB/RIF) to Predict the Sputum Smear Status of Tuberculosis Patients. Clin. Infect. Dis. 54, 384–388 (2012).
    1. van Zyl-Smit R. N. et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PloS ONE 6, e28815 (2011).
    1. Blakemore R. et al. A Multisite Assessment of the Quantitative Capabilities of the Xpert MTB/RIF Assay. Am. J. Respir. Crit. Care Med. 184, 1076–1084 (2011).
    1. Hanrahan C. F. et al. Xpert MTB/RIF as a measure of sputum bacillary burden: variation by HIV status and immunosuppression. Am. J. Respir. Crit. Care Med., 10.1164/rccm.201312-2140OC (2014).
    1. Benova L. et al. Association of BMI Category Change with TB Treatment Mortality in HIV-Positive Smear-Negative and Extrapulmonary TB Patients in Myanmar and Zimbabwe. PloS one 7, e35948 (2012).
    1. Marshall C. S. et al. Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings. PloS one 8, e68445 (2013).
    1. Theron G. et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am. J. Respir. Crit. Care Med. 184, 132–140 (2011).
    1. Theron G. et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 383, 424–435 (2013).
    1. Peter J. G. et al. Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial. Lancet Resp Med 6, 471–478 (2013).
    1. Meldau R. et al. Comparison of same day diagnostic tools including Gene Xpert and unstimulated IFN-gamma for the evaluation of pleural tuberculosis: a prospective cohort study. BMC Pulm Med 14, 58 (2014).
    1. Pandie S. et al. Diagnostic Accuracy of Quantitative PCR (Xpert MTB/RIF) for Tuberculous Pericarditis Compared to Adenosine Deaminase and Unstimulated Interferon-γ in a High Burden Setting: A Prospective Study BMC Med In press. (2014).
    1. Mayosi B. M. et al. Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. BMC Infect Dis 6, 2 (2006).
    1. Xpert MTB/RIF [package insert]. Cepheid, S., CA, 300-7810 Rev. A, April 2009.
    1. Patel V. B. et al. Diagnostic Accuracy of Quantitative PCR (Xpert MTB/RIF) for Tuberculous Meningitis in a High Burden Setting: A Prospective Study. PLoS Med 10, e1001536 (2013).
    1. Nhu N. T. Q. et al. Evaluation of GeneXpert MTB/RIF for Diagnosis of Tuberculous Meningitis. J. Clin. Microbiol. 52, 226–233 (2014).
    1. Dheda K. et al. Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting. PLoS One 4, e4689 (2009).
    1. Rachow A. et al. Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay—A Clinical Validation Study. PloS one 6, e20458 (2011).
    1. Theron G. et al. Correlation of Mycobacterium Tuberculosis Specific and Non-Specific Quantitative Th1 T-Cell Responses with Bacillary Load in a High Burden Setting. PloS one 7, e37436 (2012).
    1. Perrin F. et al. Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis. IJTLD 14, 1596–1602 (2010).
    1. Diacon A. et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur. J. Clin. Microbiol. Infect. Dis. 1–5 (2010).
    1. Pheiffer C. et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. IJTLD 12, 792–798 (2008).
    1. Bark C. M., Thiel B. A. & Johnson J. L. Pretreatment Time to Detection of Mycobacterium tuberculosis in Liquid Culture Is Associated with Relapse after Therapy. J. Clin. Microbiol. 50, 538–538 (2012).

Source: PubMed

3
Se inscrever